CTAS vs TGTX · P/E 51, rev $11.26B vs P/E 18, rev $240.3M
Cintas Corporation (CTAS) versus TG Therapeutics Inc (TGTX) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ.
Latest reported CTAS revenue for 2026-05-31 was $11.26B. Net income was $2.00B. Revenue was up 8.9% from 2025-05-31 to 2026-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
Latest reported TGTX revenue for 2026-06-30 was $240.3M. Net income was $7.8M. Revenue was up 17.3% from 2026-03-31 to 2026-06-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.
Not investment advice. Open the CTAS and TGTX stock pages for the full models.
Not investment advice.